Does Rallies track congressional trades in BMY?

Yes. Rallies tracks politician and congressional stock disclosures for BMY, including reported purchases, sales, dates, owners, and trade amounts when available.

Is BMY research on Rallies investment advice?

No. Rallies provides research, data, and educational context for BMY. It does not provide personalized investment advice.

BMY (Bristol Myers Squibb) Stock Analysis - Politician Trades

Bristol Myers Squibb (BMY) is a publicly traded Healthcare sector company. As of May 20, 2026, BMY trades at $58.52 with a market cap of $117.03B and a P/E ratio of 16.83. BMY moved +0.20% today. Year to date, BMY is +9.07%; over the trailing twelve months it is +23.49%. Its 52-week range spans $42.52 to $63.33. Analyst consensus is buy with an average price target of $64.29. Rallies surfaces BMY's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Which politicians traded BMY stock?

Recent politician trading activity in BMY includes disclosures from Julie Johnson, Julie Johnson, Gilbert Cisneros, Gilbert Cisneros, and Jefferson Shreve. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.

BMY Key Metrics

Key financial metrics for BMY
Metric	Value
Price	$58.52
Market Cap	$117.03B
P/E Ratio	16.83
EPS	$3.47
Dividend Yield	0.63%
52-Week High	$63.33
52-Week Low	$42.52
Volume	5.21M
Avg Volume	0
Revenue (TTM)	$48.19B
Net Income	$7.05B
Gross Margin	71.08%

Congressional Trades in BMY

Julie Johnson sale BMY on Dec 18, 2025 (amount: $15.00K) for Joint.
Julie Johnson sale BMY on Nov 13, 2025 (amount: $15.00K) for Joint.
Gilbert Cisneros purchase BMY on Nov 12, 2025 (amount: $15.00K).
Gilbert Cisneros sale BMY on Oct 9, 2025 (amount: $15.00K).
Jefferson Shreve sale BMY on May 12, 2025 (amount: $50.00K).

Latest BMY News

Bristol-Myers Squibb Deploys Anthropic Claude AI to 30,000 Employees for Drug Discovery — May 20, 2026
Bristol-Myers Signs $15.2B Strategic Oncology Pact in China — May 13, 2026
Bristol Myers’ Camzyos Achieves Phase 3 Success in Adolescent HCM Study — May 12, 2026
Bristol Myers Squibb Joins Jiangsu Hengrui in $15.2B Collaboration on 13 Programs — May 12, 2026
Bristol-Myers Squibb slides as Q1 beat fails to lift unchanged 2026 outlook — May 1, 2026

Recent BMY Insider Trades

Elkins David V sold 25.52K (~$1.57M) on Apr 1, 2026.
Elkins David V sold 4.48K (~$278.05K) on Apr 1, 2026.

BMY Analyst Consensus

18 analysts cover BMY: 0 strong buy, 6 buy, 12 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $64.29.

Common questions about BMY

Which politicians traded BMY stock?: Recent politician trading activity in BMY includes disclosures from Julie Johnson, Julie Johnson, Gilbert Cisneros, Gilbert Cisneros, and Jefferson Shreve. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
Does Rallies track congressional trades in BMY?: Yes. Rallies tracks politician and congressional stock disclosures for BMY, including reported purchases, sales, dates, owners, and trade amounts when available.
Is BMY research on Rallies investment advice?: No. Rallies provides research, data, and educational context for BMY. It does not provide personalized investment advice.